Professional
Added to YB: 2024-10-22
Pitch date: 2024-10-21
ABUS [bullish]
Arbutus Biopharma Corporation
+16.01%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States.
Market Cap
$869.3M
Pitch Price
$4.06
Price Target
N/A
Dividend
N/A
EV/EBITDA
-26.03
P/E
-20.12
EV/Sales
53.42
Sector
Biotechnology
Category
N/A
Show full summary:
Tourlite Capital Portfolio Holding: Arbutus Biopharma Corporation
ABUS: LNP litigation exposure via Roivant main interest. No major Q updates, but positive Roivant comments & sell-side research boosted share price. ATM offering discontinued, signaling focus shift to internal HepB asset advancement.
Read full article (1 min)